APA (7th ed.) Citation

L, C., L, S., D, F., M, B., J, S., S, S., . . . A, G. (2009). MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. Arthritis & Rheumatism, 60(3), 870. https://doi.org/10.1002/art.24351

Chicago Style (17th ed.) Citation

L, Chung, et al. "MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon: A Randomized, Controlled Trial." Arthritis & Rheumatism 60, no. 3 (2009): 870. https://doi.org/10.1002/art.24351.

MLA (9th ed.) Citation

L, Chung, et al. "MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon: A Randomized, Controlled Trial." Arthritis & Rheumatism, vol. 60, no. 3, 2009, p. 870, https://doi.org/10.1002/art.24351.